Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.

David Meek bought the company last year for the pharma industry equivalent of loose change. The company was on the brink of ...

The FDA approved the expansion of Casgevy, which had previously been greenlit for patients 12 and up, into a younger pediatric population under the agency’s Commissioner’s National Priority Voucher ...

R&D wins beyond cystic fibrosis, with the povetacicept FDA decision coming for IgA nephropathy. Click for this VRTX update.

A generic version of a breakthrough cystic fibrosis drug, manufactured in Bangladesh for a fraction of the American price, may give some families around the world an unlikely lifeline.

Geely has introduced a new entry-level SUV product in South Africa. Here's what you get for your money: ...

Eerie omens haunt this absorbing group portrait set over six months in an English village Sitting stoned on a hill above his village, a young man muses on his place in the world. Connor is proud to ...

After pausing a trial for a Moderna-partnered cystic fibrosis candidate due to subpar tolerability, Vertex Pharmaceuticals has now decided to discontinue the program entirely. Vertex initially paused ...

👉 Learn how to write a quadratic equation from standard form to vertex form by completing the square. A quadratic equation is an equation whose highest exponent in the variable(s) is 2. It is of the ...

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease. Vertex ...

March 9 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Monday that its experimental drug sharply reduced a key sign of kidney damage in a late‑stage ‌trial, putting the company on ...